

Expected *submission* timelines

2024

tolebrutinib RMS	rilzabrutinib ITP
tolebrutinib nrSPMS	fitusiran Hemophilia A/B
Sarclisa 1L Newly Diag. MM Tt (IMROZ)	venglustat GM2 gangliosidosis
	MenQuadfi 6w+

→

2025

Dupixent CSU	Nexviazyme Pompe Disease Infantile Onset
Dupixent Bullous pemphigoid	venglustat Fabry Disease
itepekimab COPD	Sarclisa SubQ 3L RR MM (IRAKLIA)
tolebrutinib PPMS	Sarclisa 1L Newly Diag. MM Tt (GMMG)
	SP0087 Purified vero rabies vaccine

→

2026 and beyond

Dupixent CPUO	venglustat Gaucher Type 3
amlitelimab Atopic Dermatitis	fitusiran Hemophilia A/B ped
frexalimab RMS	Sarclisa Smoldering MM
frexalimab nrSPMS	SP0282 Invasive ExPEC disease
riliprubart SOC-Refractory CIDP	SP0125 RSV toddler
riliprubart IVIg-Treated CIDP	SP0202 Prevention of pneumococcal disease
	SP0218 Yellow fever

→

As of December 31, 2023. Excluding Phase 1 and 2 (without Proof of Commercial Concept) and selected submissions. Projects within a specified year are not arranged by expected time of submission.